By Gerberal | July 12, 2026 | 10 min read
During the first week of July 2026, as semiconductor stocks were melting down — erasing roughly $800 billion in market value in five trading sessions — something quietly remarkable happened in a completely different sector. Twenty-nine Chinese pharmaceutical and healthcare funds gained more than 10%. While chip investors were panic-selling, pharma investors were collecting double-digit weekly returns, entirely uncorrelated to the AI selloff.
This is the healthcare sector in a nutshell: defensive enough to hold up when growth cracks, innovative enough to deliver real returns, and — in China's case — beaten down enough to offer genuine contrarian value. For context on how healthcare fits alongside other defensive sectors, see our energy sector ETF guide for another sector-level comparison.
This article compares the three healthcare ETF ecosystems: US broad healthcare (the safe core), US biotech (the high-risk, high-reward satellite), and China pharma (the beaten-down contrarian trade).
The Healthcare ETF Landscape
| ETF | Ticker | Expense Ratio | AUM | Holdings | Strategy | Yield |
|---|---|---|---|---|---|---|
| Health Care Select Sector SPDR | XLV | 0.09% | ~$40B | ~65 stocks | US large-cap healthcare; market-cap weighted | ~1.5% |
| Vanguard Health Care ETF | VHT | 0.10% | ~$20B | ~420 stocks | Broad US healthcare; all cap sizes | ~1.3% |
| iShares Biotechnology ETF | IBB | 0.45% | ~$8B | ~230 stocks | US biotech; market-cap weighted | ~0.3% |
| SPDR S&P Biotech ETF | XBI | 0.35% | ~$8B | ~135 stocks | US biotech; equal-weight | ~0.2% |
| iShares US Medical Devices | IHI | 0.40% | ~$6B | ~60 stocks | Medical devices; market-cap weighted | ~0.5% |
Strategy 1: XLV — The Defensive Core
XLV is the default US healthcare ETF: ~65 large-cap healthcare stocks spanning pharmaceuticals, biotech, medical devices, health insurers, and healthcare providers. At 0.09%, it's effectively free to own.
XLV top holdings (mid-2026):
| Company | Weight | Sub-sector | What They Do |
|---|---|---|---|
| Eli Lilly | ~13% | Pharmaceuticals | GLP-1 drugs (Mounjaro/Zepbound); the most valuable healthcare company |
| UnitedHealth Group | ~9% | Managed Care | Largest US health insurer |
| Johnson & Johnson | ~8% | Diversified | Pharma + medical devices; 130+ years old |
| AbbVie | ~6% | Pharmaceuticals | Humira successor drugs; immunology |
| Merck | ~5% | Pharmaceuticals | Keytruda (cancer immunotherapy); vaccines |
| Thermo Fisher Scientific | ~4% | Life Sciences Tools | Lab equipment and diagnostics |
XLV is concentrated in the top names — Eli Lilly alone is 13% of the fund, largely driven by the GLP-1 weight loss drug revolution that has reshaped the pharmaceutical industry since 2023.
XLV Performance: Steady, Not Spectacular
| Period | XLV | VOO (S&P 500) | Difference |
|---|---|---|---|
| YTD 2026 | +8% | +11% | −3% |
| 2025 | +12% | +25% | −13% |
| 2024 | +10% | +26% | −16% |
| 2023 | +2% | +26% | −24% |
| 2022 (bear market) | −2% | −19% | +17% |
| 10-Year Ann. (2016–2025) | +11% | +14% | −3% |
XLV underperforms in bull markets — sometimes dramatically. But in 2022, when the S&P 500 fell 19%, XLV fell only 2%. In the 2008 financial crisis, healthcare fell roughly half as much as the broad market. This pattern — modest underperformance in good times, significant outperformance in bad times — is the hallmark of a defensive sector.
Best for: Core healthcare exposure. Investors who want sector-level diversification without stock-level risk. Anyone who believes the market is due for a correction and wants to rotate toward defensives without going to cash. For a broader framework on how sector ETFs fit into a diversified portfolio, see our core-satellite ETF portfolio guide.
Strategy 2: IBB vs XBI — The Biotech Duality
Biotech is not healthcare. Healthcare is an established industry selling drugs, devices, and insurance to stable, growing demand pools. Biotech is a venture-capital-like bet on scientific discovery — most biotech companies lose money, have no approved products, and trade on the binary outcome of clinical trial results.
IBB vs XBI: The Same Sector, Radically Different Portfolios
| Dimension | IBB (iShares Biotech) | XBI (SPDR Biotech) |
|---|---|---|
| Weighting | Market-cap weighted | Equal-weight |
| Holdings | ~230 | ~135 |
| Top Holding | Amgen (~8%) | Any stock (~0.7%) |
| Top 5 Weight | ~35% | ~3.5% |
| Large-cap (>$10B) | ~70% of fund | ~30% of fund |
| Small/mid-cap (<$5B) | ~15% | ~45% |
| Expense Ratio | 0.45% | 0.35% |
| Yield | ~0.3% | ~0.2% |
IBB is essentially a large-cap pharma ETF with a biotech label — Amgen, Gilead, Vertex, and Regeneron dominate. These are profitable, established companies. XBI is a genuine small-cap biotech bet — no single stock can dominate, and the portfolio's fate depends on the aggregate success of clinical-stage companies.
Performance
| Period | IBB (Large Biotech) | XBI (Small Biotech) | Difference |
|---|---|---|---|
| YTD 2026 | +6% | +9% | −3% |
| 2025 | +8% | +14% | −6% |
| 2024 | +5% | +2% | +3% |
| 2023 | −3% | +8% | −11% |
| 2022 | −12% | −26% | +14% |
| 5-Year Ann. (2021–2025) | +5% | −2% | +7% |
XBI is a rollercoaster: −26% in 2022, +8% in 2023, +2% in 2024, +14% in 2025. IBB is steadier but has compounded at only 5% annualized over five years — well below the S&P 500. The structural problem for biotech ETFs: the winners (companies that get drugs approved) graduate to large-cap status and get capped or diluted in equal-weight portfolios, while the losers (companies whose trials fail) drag down returns until they drop out of the index.
Bottom line on biotech: IBB for cautious biotech exposure. XBI for genuine small-cap biotech exposure — but only if you're prepared for 20-30% drawdowns during risk-off periods. Neither has been a good long-term hold compared to simply buying XLV or the S&P 500.
The GLP-1 Phenomenon
One reason to consider healthcare in 2026: the GLP-1 drug class (Eli Lilly's Mounjaro/Zepbound, Novo Nordisk's Ozempic/Wegovy) has become one of the largest pharmaceutical opportunities in history. GLP-1s are projected to exceed $150 billion in annual sales by 2030, driven by obesity, diabetes, and emerging evidence of cardiovascular and kidney benefits.
XLV and IBB capture this through Eli Lilly (~13% of XLV) and Novo Nordisk (~8% of IBB). IHI (medical devices) captures it indirectly — GLP-1s are delivered via injection pens, and the device ecosystem around drug delivery benefits from volume growth. For investors interested in how factor tilts can complement sector exposure, our factor investing guide discusses quality and momentum factors that often overlap with healthcare stock characteristics.
Strategy 3: China Pharma — The Contrarian Trade
China's pharmaceutical sector has been in a brutal bear market. After peaking in mid-2020, the CSI Healthcare Index fell roughly 55% to its 2023 lows, driven by:
- National Reimbursement Drug List (NRDL) price cuts: The Chinese government's centralized drug procurement system slashes prices by 50-80% on generic and even some innovative drugs — good for patients, devastating for pharma margins.
- Anti-corruption campaign: A 2023-2024 crackdown on pharmaceutical marketing practices disrupted sales operations across the industry.
- Broad China equity bear market: The entire China stock market sold off from 2021 to 2024, and healthcare was one of the hardest-hit sectors.
By mid-2026, the narrative is shifting. The anti-corruption campaign is winding down. The worst of the price cuts may be behind, with innovative drugs (as opposed to generics) receiving more favorable pricing. And the GLP-1 boom is global — Chinese pharma companies are developing their own GLP-1 drugs for the world's largest diabetes and obesity market.
China Healthcare ETFs
| ETF | Ticker | Expense Ratio | AUM | Market | Strategy |
|---|---|---|---|---|---|
| KraneShares MSCI All China Health Care | KURE | 0.65% | ~$50M | US-listed | Broad China healthcare; onshore + offshore |
| ChinaAMC CSI Medical ETF (A-share) | 512170 | 0.50% | ~¥15B | Onshore | CSI Medical Index; medical devices + services |
| E Fund CSI Healthcare ETF (A-share) | 512010 | 0.50% | ~¥8B | Onshore | CSI Healthcare; pharma + biotech + services |
| GF CSI Innovative Drug ETF (A-share) | 515120 | 0.50% | ~¥5B | Onshore | Innovative drug companies; biotech focus |
KURE is the only US-listed option but is small ($50M AUM), illiquid, and expensive at 0.65%. For investors with A-share access, 512170 (CSI Medical) is the largest and most liquid onshore option. For more on navigating A-share ETF liquidity and the cross-border mechanics, see our China A-share industry ETF guide.
China Pharma Performance
| Period | KURE (China Healthcare) | IBB (US Biotech) | XLV (US Healthcare) |
|---|---|---|---|
| YTD 2026 | +18% | +6% | +8% |
| July Week 1, 2026 | +12% | −2% | −1% |
| 2025 | +15% | +8% | +12% |
| 5-Year Ann. (2021–2025) | −8% | +5% | +11% |
The 5-year number (−8% annualized) tells the story of China pharma's bear market. The 2025-2026 recovery (+15-18% annualized) suggests the worst may be over. The July 2026 tech-selloff rally (+12% in one week, completely uncorrelated to AI) highlights the sector's value as a diversifier.
The case for China pharma in 2026:
- Valuation reset: After a 55% peak-to-trough decline, China pharma trades at roughly 15-20x forward earnings — cheaper than US pharma (18-22x) despite faster underlying demand growth from China's aging population.
- Policy tailwinds: The government is shifting from "cost containment at all costs" to "support innovative drug development" — recognizing that a domestic innovative pharma industry is a strategic asset.
- GLP-1 opportunity: Chinese companies are developing GLP-1 drugs for the domestic market (140 million diabetics, 500+ million overweight/obese). The market opportunity dwarfs the US.
- Portfolio diversification: China pharma's correlation with US tech is roughly 0.3 — providing genuine diversification when you need it most (tech selloffs).
- Demographics as destiny: China's 60+ population will exceed 400 million by 2035. Healthcare spending rises exponentially with age.
The case against:
- Policy risk is real and unpredictable — the government can and will intervene in drug pricing
- Most Chinese pharma companies are generic manufacturers with low margins, not innovative drug developers
- KURE is too small and too expensive; the real opportunities are only accessible via A-share accounts
- The 5-year track record is terrible; catching a falling knife is a risk
Portfolio Integration
Defensive Healthcare Allocation
| Investment | Allocation | Expense Ratio | Role |
|---|---|---|---|
| XLV (US Healthcare) | 5-10% | 0.09% | Core defensive sector exposure |
| IBB (US Biotech) | 0-5% | 0.45% | Optional; large-cap biotech satellite |
| XBI (US Biotech, equal weight) | 0-3% | 0.35% | High-risk; only for aggressive portfolios |
| KURE (China Healthcare) | 0-5% | 0.65% | Contrarian; only if you can tolerate illiquidity |
| Total Healthcare | 5-15% | — | Keep sector bets manageable |
Sizing Guidelines
| Portfolio Type | Healthcare Allocation | Mix |
|---|---|---|
| Conservative | 5-8% (XLV only) | Simple; defensive |
| Moderate | 8-12% (XLV + small IBB) | Core healthcare + some biotech |
| Aggressive / Contrarian | 10-15% (XLV + IBB/XBI + KURE) | Multi-market healthcare bet |
The Bottom Line
Healthcare is the sector that performs best when everything else is falling apart. July 2026's semiconductor selloff — and the simultaneous 12% rally in Chinese pharma — is a textbook demonstration of why you want some healthcare exposure in a diversified portfolio.
For most investors, XLV at 0.09% is the only healthcare ETF you need. It captures the GLP-1 revolution (Eli Lilly, 13%), the steady cash flows of health insurers (UnitedHealth, 9%), and the diversification of medical devices and pharma — all for less than the cost of a cup of coffee per year.
China pharma is the highest-risk, highest-potential-reward healthcare trade. After a 55% bear market, valuations are low, demographics are favorable, and policy is pivoting from hostile to supportive. But the sector is accessible only through small, expensive ETFs (KURE) or onshore A-share products. It's a satellite, not a core holding — sized at 2-5% for investors willing to accept China-specific policy risk in exchange for genuinely uncorrelated upside.
Continue reading: For healthcare's role within a broader defensive allocation, see our core-satellite portfolio guide. If you're comparing the fee structures across US and China-domiciled healthcare ETFs, our US vs China ETF fee comparison breaks down the total cost of ownership.
Sources
- State Street Global Advisors — XLV (Health Care Select Sector SPDR) fact sheet and holdings, 2026
- iShares (BlackRock) — IBB fund documentation, biotech sub-industry weights and holdings
- KraneShares — KURE (MSCI All China Health Care) fund prospectus and country exposure data
- China Securities Regulatory Commission (CSRC) — Drug pricing reform announcements and National Reimbursement Drug List updates
- Evaluate Pharma — GLP-1 drug class sales forecasts and market projections, 2026
- ChinaAMC / E Fund / GF Fund — Onshore CSI Healthcare ETF fact sheets and AUM data
- World Health Organization (WHO) — Global pharmaceutical market growth trends and China healthcare expenditure projections
- Goldman Sachs Research — "The GLP-1 Revolution" thematic report on obesity drug market sizing
Disclaimer: ETF Bridge is an educational resource. This article does not constitute investment advice. Healthcare and biotechnology ETFs carry sector concentration risk, regulatory risk (drug pricing, FDA/CFDA approval), and clinical trial binary risk. International healthcare ETFs carry currency risk and country-specific regulatory uncertainty. Past performance does not guarantee future results. Always conduct your own due diligence before investing.